Critical care (London, England), 2020-07, Vol.24 (1), p.392-392, Article 392
2020
Details
- Autor(en) / Beteiligte
- Titel
- Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
- Ist Teil von
- Critical care (London, England), 2020-07, Vol.24 (1), p.392-392, Article 392
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
- Beschreibungen/Notizen
- Eleven adults with reverse transcriptase polymerase chain reaction-confirmed SARS-CoV-2 infection were admitted to the intensive care unit (ICU) at The University of Tokyo Hospital between April 6 and April 21, 2020, and treated with nafamostat mesylate in combination with favipiravir. [...]nafamostat mesylate therapy in combination with favipiravir may allow blockade of virus entry and replication, as well as inhibition of pathogenic host response, i.e., hyper-coagulopathy. Mechanical ventilation SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2 TMPRSS2: Transmembrane protease serine 2 VV-ECMO: Venovenous extracorporeal membrane oxygenation 1.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1364-8535eISSN: 1466-609XDOI: 10.1186/s13054-020-03078-zTitel-ID: cdi_doaj_primary_oai_doaj_org_article_80eedbb089b84f8cba2b29563792cb98
- Format
- –
- Schlagworte
- Aged, Amides - therapeutic use, Benzamidines, Combination drug therapy, Coronavirus Infections - drug therapy, Coronaviruses, COVID-19, COVID-19 Drug Treatment, Critical care, Critical Illness, Critically ill persons, Drug therapy, Drug Therapy, Combination, Favipiravir, Female, Guanidines - therapeutic use, Humans, Influenza, Intensive care, Male, Methods, Middle Aged, Middle East respiratory syndrome, Mortality, Patients, Protease inhibitors, Pyrazines - therapeutic use, Research Letter, Respiratory diseases, Severe acute respiratory syndrome coronavirus 2, Treatment Outcome, Ventilators, Viruses